Recipharm Unit Files for Infectious Disease Treatment

RPH Pharmaceuticals, a subsidiary of Recipharm AB, has filed an application for an undisclosed infectious disease drug product in a range of European countries. The product has been developed through a partnership with Swedish pharmaceutical company, Astimex Pharma AB, which will to market the product in the Nordic market.
 
The product, owned by RPH Pharmaceuticals, is a “first-in-class generic” and will be licensed to third parties for distribution in markets where Astimex presently is not represented.
 
Astimex and RPH have expanded their collaboration with another manufacturing and development project in which the drug target is another first-in-class generic approved for use in most of the North European markets. Under the collaboration, Recipharm builds a registration dossier while Astimex takes full responsibility for sales and distribution in the Swedish market; RPH Pharmaceuticals can out-license sales and distribution rights in other markets.